The pharmaceutical industry is a high value-added industry and Korea is now more interested in new drugs than ever before.

As interest has increased, the names of pharmaceutical companies that have reported news such as clinical failures, discontinuations, or controversy about efficacy are very popular on the Internet.

It is possible. Samsung and Celltrion's biosimilars are being recognized in the US and Europe, and the government is drawing blueprints for preferential treatment of new drug prices under the development policy of the pharmaceutical industry.

But it should be clear. If success is easy, it is not a new drug in the first place. According to the analysis of 9,98